United States Patients’ Perspective of Living With Migraine: Country‐Specific Results From the Global “My Migraine Voice” Survey
Background Migraine is associated with debilitating symptoms that can affect daily functioning. “My Migraine Voice” was a large, cross‐sectional, multi‐country online survey aimed at understanding disease burden directly from people with migraine. Objective This study reports on the social and econo...
Saved in:
Published in: | Headache Vol. 60; no. 7; pp. 1351 - 1364 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
Wiley Subscription Services, Inc
01-07-2020
John Wiley and Sons Inc |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background
Migraine is associated with debilitating symptoms that can affect daily functioning. “My Migraine Voice” was a large, cross‐sectional, multi‐country online survey aimed at understanding disease burden directly from people with migraine.
Objective
This study reports on the social and economic impacts of migraine, specifically the impact on activities of daily living and the costs of migraine, from the point of view of people with migraine in the United States.
Methods
The online survey was administered to adults with a self‐reported diagnosis of migraine who experienced 4 or more monthly migraine days each month for the previous 3 months. Prespecified screening quotas were used so that 90% of respondents reported current or past use of preventive migraine medication, 80% of whom switched treatment (ie, changed their prescribed preventive medication at least once). The remaining 10% were preventive treatment naïve (ie, never used any prescribed preventive medication). Burden of migraine on activities of daily living and caregivers (eg, functional limitations, fear of next migraine attack, sleep problems) and economic burden (eg, out‐of‐pocket costs, impact on work productivity using the validated work productivity and activity impairment questionnaire) reported by respondents from the United States are presented. Results are stratified by employment status, migraine frequency (chronic vs episodic migraine), and history of preventive treatment.
Results
Thousand hundred and one individuals with migraine from the United States responded to the survey. Respondents reported limitations completing daily activities during all migraine phases, including during the premonitory/aura and postdrome phases. Most (761/1101 (69%)) relied on family, friends, or others for help with daily tasks and reported being helped a median of 9 days (25th percentile 5 days, 75th percentile 15 days) within the last 3 months. Respondents with chronic migraine reported being helped for more days (median 10 days, 25th percentile 5 days, 75th percentile 23 days) in the last 3 months. Almost all (962/1101 (87%)) experienced sleep difficulties and 41% (448/1101) (48% (336/697) of those with 2 or more preventive treatment failures) were very or extremely fearful of a next migraine attack. Median (25th percentile, 75th percentile) monthly out‐of‐pocket costs of $90.00 ($30.00, $144.00) in doctor’s fees (n = 504), $124.00 ($60.00, $234.00) in health insurance (n = 450), $40.00 ($20.00, $100.00) for prescriptions (n = 630), and $50.00 ($0.00, $100.00) for complementary therapies (n = 255) were reported. Those with 2 or more preventive treatment failures reported higher monthly out‐of‐pocket doctor fees (median $99.00 ($30.00, $150.00), n = 388). Among employed respondents (n = 661), migraine resulted in 22% absenteeism, 60% presenteeism, 65% work productivity loss, and 64% activity impairment.
Conclusions
Migraine impacts individuals’ activities of daily living, work‐life, and financial status, especially individuals with high needs, namely those with 4 or more monthly migraine days and prior treatment failures. People with migraine are impaired during all migraine phases, experience fear of their next migraine attack and sleep difficulties, and pay substantial monthly out‐of‐pocket costs for migraine. Burden is even greater among those who have had 2 or more preventive treatment failures. Impacts of migraine extend beyond probands to caregivers who help people with migraine with daily tasks, employers who are affected by employee absenteeism, presenteeism, and reduced productivity, and society which is burdened by lost and reduced economic productivity and healthcare costs. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Conflict of Interest: Sarah N Gibbs is an employee of the Partnership for Health Analytic Research (PHAR) LLC, which was paid by Amgen Inc. to conduct the analysis described in this manuscript. Shweta Shah is an employee of, and shareholder in, Amgen Inc. Chinmay Deshpande is an employee of, and shareholder in, Novartis Pharmaceuticals Corporation. Mark Bensink is an employee of, and shareholder in, Amgen Inc. Michael S Broder is an employee of the Partnership for Health Analytic Research (PHAR) LLC, which was paid by Amgen Inc. to conduct the analysis described in this manuscript. Paula K Dumas is the President of the World Health Education Foundation, a 501c3 which receives funding from Amgen Inc., to do patient education, research, and advocacy. Dawn C. Buse, PhD has received grant support and honoraria from Allergan, Amgen, Avanir, Biohaven, Eli Lilly, Novartis and Promius/Dr. Reddys. She has not been paid by any company for work writing manuscripts, or writing or presenting abstracts, posters or platforms. She serves on the editorial boards of Current Pain and Headache Reports, the Journal of Headache and Pain, Pain Medicine News, and Pain Pathways magazine. Pamela Vo is an employee of, and shareholder in, Novartis Pharmaceuticals Corporation. Todd Schwedt has served as a consultant for Alder, Allergan, Amgen, Avanir, Cipla, Dr. Reddy’s, Eli Lilly, Ipsen Bioscience, Nocira, Novartis, Salvia, Teva, and Xoc. He has stock options in Aural Analytics, Nocira, and Second Opinion. He has received research funding from Amgen, American Migraine Foundation, Arizona State University, Henry Jackson Foundation, National Institutes of Health, Patient‐Centered Outcomes Research Institute, and U.S. Department of Defense. He serves on the Board of Directors for the American Headache Society and the International Headache Society. Funding: This work was co‐funded by Novartis Pharmaceutical Corporation and Amgen Inc. The “My Migraine Voice” survey was funded by Novartis Pharmaceutical Corporation. |
ISSN: | 0017-8748 1526-4610 |
DOI: | 10.1111/head.13829 |